Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05664815

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management

Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-09-19

66

Participants Needed

5

Research Sites

127 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to demonstrate, during the first standard surgical management of patients with stage II MRONJ, the effect of the implantation of a cryopreserved hAM on the maxillomandibular bone, on the healing of the oral mucosa.

CONDITIONS

Official Title

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women over the age of 18
  • Treated for cancer with bisphosphonates, Denosumab, or anti-angiogenic therapies, including past or current treatment
  • Clinically and radiologically confirmed stage II MRONJ, including maxilla cases without bucco-sinus communication after necrotic bone removal
  • Patients of childbearing age using contraception or postmenopausal
  • Signed informed consent to participate and comply with study requirements
  • Affiliated with a French social security scheme or beneficiary of such a scheme
Not Eligible

You will not qualify if you...

  • Life expectancy under 6 months as assessed by oncologists
  • Presence of ongoing cervico-facial or oral cancer
  • History of oral or cervico-facial radiotherapy
  • Allergy to amoxicillin-clavulanic acid or clindamycin-metronidazole combination
  • Contraindication to surgery under general or local anesthesia
  • MRONJ stage I or stage III
  • Stage II MRONJ patients with osteoporosis only
  • Use of long-term corticosteroids or immunosuppressants
  • Presence of bone diseases like brittle bone disease, primary bone tumors, or metabolic bone disorders
  • Childbearing age patients without contraception
  • Legal incapacity or limited legal capacity
  • Expected lack of cooperation in the study
  • Not affiliated with a social security scheme
  • Under guardianship, curatorship, or imprisonment
  • Refusal to participate in the research
  • Participation in another clinical research study
  • Discovery during surgery of stage III MRONJ or spontaneous healing after sequestrectomy
  • Need for invasive dental surgeries related to bone exposure during inclusion
  • Mandibular metastases during inclusion
  • Deterioration of health due to cancer during inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

CHU de Besancon

Besançon, France, 25030

Actively Recruiting

2

CHU Bordeaux Pellegrin

Bordeaux, France

Not Yet Recruiting

3

CHU de Dijon

Dijon, France

Not Yet Recruiting

4

CHR Metz Thionville

Metz, France

Not Yet Recruiting

5

CHU de Reims

Reims, France

Not Yet Recruiting

Loading map...

Research Team

F

Florelle GINDRAUX, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management | DecenTrialz